source
- Cytokinetics aims for broader Myqorzo approval next year after supportive trial dataCytokinetics reported new data on its cardiac therapy Myqorzo, presented at a European scientific meeting. The results reinforce the drug’s efficacy in a specific heart muscle disorder. The compan…
- Multispecific antibodies push CDMOs to redesign development platformsManufacturers are moving beyond traditional monoclonal-antibody platforms as multispecific therapeutics gain traction. The new design model relies on molecular engineering, advanced analytics, and…